Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products

Seminars in Thrombosis and Hemostasis

Volumn 42, Issue 5, 2016, Pages 518-525

  Berntorp, Erik ^a   Andersson, Nadine G ^b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

factor IX; factor VIII; hemophilia A; hemophilia B; prophylaxis

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; IMMUNOGLOBULIN G; MACROGOL; F8 PROTEIN, HUMAN; HYBRID PROTEIN;

ARTICLE; DRUG HALF LIFE; HEMOPHILIA; HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SUBSTITUTION THERAPY; CLINICAL TRIAL (TOPIC); HEMOPHILIA A;

CLINICAL TRIALS AS TOPIC; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HUMANS; RECOMBINANT FUSION PROTEINS;

EID: 84976870484     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0036-1571315     Document Type: Article

References (34)

1. Lövdahl S., Henriksson K. M., Baghaei F., et al. Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden. Haemophilia: 2013; 19 3 362 369
2. Fischer K., Steen Carlsson K., Petrini P., et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood: 2013; 122 7 1129 1136
3. Berntorp E., Fischer K., Miners A. Models of prophylaxis. Haemophilia: 2012; 18 04 136 140
4. Berntorp E., Astermark J., Björkman S., et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia: 2003; 9 01 1 4
5. Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol: 2007; 138 5 580 586
6. Lock J., Raat H., Duncan N., et al. Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the VERITAS-Pro scale. Haemophilia: 2014; 20 5 616 623
7. Dumont J. A., Low S. C., Peters R. T., Bitonti A. J. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs: 2006; 20 3 151 160
8. Ober R. J., Martinez C., Lai X., Zhou J., Ward E. S. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci U S A: 2004; 101 30 11076 11081
9. Kim J., Bronson C. L., Hayton W. L., et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol: 2006; 290 2 G352 G360
10. Mahlangu J., Powell J. S., Ragni M. V., et al. A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood: 2014; 123 3 317 325
11. Young G., Mahlangu J., Kulkarni R., et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost: 2015; 13 6 967 977
12. Powell J. S., Pasi K. J., Ragni M. V., et al. B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med: 2013; 369 24 2313 2323
13. Fischer K. KR, Bradbury M., Ragni M., et al. Pharmacokinetics of recombinant factor IX Fc fusion protein (rFIXFc) in pediatric subjects with hemophilia B: an interim analysis of the kids B-long study. Blood: 2013; 122 3599
14. Powell J., Shapiro A., Ragni M., et al. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. Br J Haematol: 2015; 168 1 113 123
15. Santagostino E., Jacobs I. C., Voigt C., Feussner A., Limsakun T. Pharmacokinetic results of two phase III clinical studies of coagulation factor IX (recombinant) albumin fusion protein (rIX-FP) in previously treated patients. Blood: 2014; 124 21 1491
16. Giangrande P. CP, Ehrenforth S., Hanabusa H., et al. Abstracts ISTH: Clinical evaluation of novel recombinant glycopegylated FVIII (turoctocog alfa pegol, N8- GP): efficacy and safety in previously treated patients with severe hemophilia. A--results of a pathfinder 2 international trial. Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis; June 20-25, 2015; J Thromb Haemost: 2015; 13 02 1 997
17. Coyle T. E., Reding M. T., Lin J. C., Michaels L. A., Shah A., Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost: 2014; 12 4 488 496
18. Konkle B. A., Stasyshyn O., Chowdary P., et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood: 2015; 126 9 1078 1085
19. Collins P. W., Young G., Knobe K., et al. paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood: 2014; 124 26 3880 3886
20. Carcao M., Zak M., Abdul Karim F., et al. Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) in prophylaxis and treatment of bleeding episodes in previously treated pediatric hemophilia B patients. Blood: 2014; 124 21 1513
21. Ragni M. V., Malec L. M. Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance. Expert Rev Hematol: 2014; 7 6 747 755
22. Fijnvandraat K., Berntorp E., ten Cate J. W., et al. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost: 1997; 77 2 298 302
23. Björkman S., Carlsson M., Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol: 1994; 46 4 325 332
24. Collins P. W., Fischer K., Morfini M., Blanchette V. S., Björkman S.; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia: 2011; 17 1 2 10
25. Lindvall K., Astermark J., Björkman S., et al. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia: 2012; 18 6 855 859
26. den Uijl I. E., Fischer K., Van Der Bom J. G., Grobbee D. E., Rosendaal F. R., Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia: 2011; 17 1 41 44
27. Ahnström J., Berntorp E., Lindvall K., Björkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia: 2004; 10 6 689 697
28. Collins P. W., Blanchette V. S., Fischer K., et al. rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost: 2009; 7 3 413 420
29. Manco-Johnson M. J., Abshire T. C., Shapiro A. D., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med: 2007; 357 6 535 544
30. Feldman B. M., Pai M., Rivard G. E., et al. Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost: 2006; 4 6 1228 1236
31. Gringeri A., Lundin B., von Mackensen S., Mantovani L., Mannucci P. M., Group E. S.; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost: 2011; 9 4 700 710
32. Berntorp E., Shapiro A. D. Modern haemophilia care. Lancet: 2012; 379 9824 1447 1456
33. Armstrong J. K., Hempel G., Koling S., et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer: 2007; 110 1 103 111
34. Nathwani A. C., Reiss U. M., Tuddenham E. G., et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med: 2014; 371 21 1994 2004